Chronic Kidney Disease in Children Clinical Presentation
- Author: Sanjeev Gulati, MBBS, MD, DNB(Peds), DM, DNB(Neph), FIPN(Australia), FICN, FRCPC(Canada); Chief Editor: Craig B Langman, MD more...
History and Physical Examination
Chronic kidney disease (CKD) is asymptomatic in its earliest stages (stage I and stage II), although urinalysis findings or blood pressure may be abnormal. As chronic kidney disease progresses to more advanced stages, signs and symptoms greatly increase.
Polydipsia and nocturia (secondary to a reduced capacity to concentrate the urine) may be one of the earliest symptoms that indicate a diagnosis of chronic kidney disease in an otherwise healthy-looking child who has tubulointerstitial kidney disease.
The signs and symptoms in advanced chronic kidney disease may include the following:
- Volume overload
- Hyperkalemia
- Metabolic acidosis
- Hypertension
- Anemia
- Bone disease (termed osteodystrophy)
- Cardiovascular disease
- Anorexia, nausea, vomiting
The absolute serum levels of blood urea nitrogen (BUN) or creatinine do not directly correlate with the development of these symptoms; however, estimated glomerular filtration rate (eGFR) seems to be associated with a stronger correlation.
The physical findings vary depending on the severity of kidney failure and can range from an absence of any physical findings to the presence of one or more of the following:
- Anemia
- Short stature
- Hypertension
- Osteodystrophy
- Cardiac abnormalities (eg, left ventricular hypertrophy [LVH], pericarditis)
- Peripheral neuropathy
- Central nervous system (CNS) abnormalities (eg, ranging from loss of concentration and lethargy to seizures, coma)
Approximately 50-100% of patients with end-stage renal disease (ESRD) also have at least one dermatologic condition. In addition, uremia and conditions associated with renal replacement therapy often give rise to numerous and, often, relatively unique cutaneous disorders. These dermatologic manifestations of renal disease may be divided into 3 general associated with ESRD, uremia, or renal transplantation. Discussion of the common cutaneous disorders in renal disease is beyond the scope of this article; see Dermatologic Manifestations of Renal Disease.
The image below illustrates several uremia-related cutaneous disorders.
Hands of a transfusion-dependent patient on long-term hemodialysis. Several uremia-related cutaneous disorders are visible. The pigmentary alteration results from retained urochromes and hemosiderin deposition. The large bullae are consistent with either porphyria cutanea tarda or the bullous disease of dialysis. All nails show the distal brown-red and proximal white coloring of half-and-half nails. Staging
The Kidney Disease Outcomes Quality Initiative (KDOQI) recommended the following classification of chronic renal disease by stage[4, 10] :
- Stage I disease is defined by a normal glomerular filtration rate (GFR) (> 90 mL/min per 1.73 m2) and persistent albuminuria
- Stage II disease is characterized by a GFR of 60-89 mL/min per 1.73 m2 and persistent albuminuria
- Stage III disease is characterized by a GFR of 30-59 mL/min per 1.73 m2
- Stage IV disease is characterized by a GFR of 15-29 mL/min per 1.73 m2
- Stage V disease is characterized by a GFR of less than 15 mL/min per 1.73 m2 or end-stage renal disease (ESRD)
US Renal Data System (USRDS). 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010. Available at http://www.usrds.org/adr.htm. Accessed June 13, 2011.
[Guideline] Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. Jan 2001;37(1 Suppl 2):S66-70. [Medline].
[Guideline] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. Feb 2002;39(2 Suppl 1):S1-266. [Medline].
[Guideline] KDOQI. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis. Mar 2009;53(3 Suppl 2):S11-104. [Medline].
Seikaly MG, Ho PL, Emmett L, et al. Chronic renal insufficiency in children: the 2001 Annual Report of the NAPRTCS. Pediatr Nephrol. Aug 2003;18(8):796-804. [Medline].
Gulati S, Mittal S, Sharma RK, Gupta A. Etiology and outcome of chronic renal failure in Indian children. Pediatr Nephrol. Sep 1999;13(7):594-6. [Medline].
Ardissino G, Dacco V, Testa S, et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics. Apr 2003;111(4 Pt 1):e382-7. [Medline].
[Best Evidence] Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Hernandez GT, O'Hare AM. White/black racial differences in risk of end-stage renal disease and death. Am J Med. Jul 2009;122(7):672-8. [Medline].
Craven AM, Hawley CM, McDonald SP, et al. Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis. Perit Dial Int. Mar-Apr 2007;27(2):184-91. [Medline].
[Guideline] Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. Jun 2003;111(6 Pt 1):1416-21. [Medline].
Eknoyan G. The importance of early treatment of the anaemia of chronic kidney disease. Nephrol Dial Transplant. 2001;16 Suppl 5:45-9. [Medline].
Sanchez CP. Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Paediatr Drugs. 2003;5(11):763-76. [Medline].
[Guideline] Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis. Nov 2005;46(5):925-32. [Medline].
Seeherunvong W, Abitbol CL, Chandar J, Zilleruelo G, Freundlich M. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr. Jun 2009;154(6):906-11.e1. [Medline].
Salusky IB. A new era in phosphate binder therapy: what are the options?. Kidney Int Suppl. Dec 2006;(105):S10-5. [Medline].
Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr. Apr 2002;14(2):197-204. [Medline].
Soergel M, Schaefer F. Effect of hypertension on the progression of chronic renal failure in children. Am J Hypertens. Feb 2002;15(2 Pt 2):53S-56S. [Medline].
Swinford RD, Portman RJ. Measurement and treatment of elevated blood pressure in the pediatric patient with chronic kidney disease. Adv Chronic Kidney Dis. Apr 2004;11(2):143-61. [Medline].
Haffner D, Schaefer F, Nissel R, et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med. Sep 28 2000;343(13):923-30. [Medline].
Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database of Systematic Reviews. 2012.
Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol. Oct 2008;23(10):1823-9. [Medline].
Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol. Jul 24 2007;[Medline].
Mak RH. Chronic kidney disease in children: state of the art. Pediatr Nephrol. Oct 2007;22(10):1687-8. [Medline].

